Physician profile
Patrick Enright
NPI 1417934829
$167.34
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $11.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.95 | 2019 | |
| Glaxosmithkline, LLC. | $26.54 | 2019 | |
| Astellas Pharma US INC | $20.29 | 2019 | |
| Sanofi Pasteur INC. | $15.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.34 | 2019 | |
| Novo Nordisk INC | $13.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.06 | 2019 | |
| Lilly USA, LLC | $12.46 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.96 | 2019 | |
| Merck Sharp & Dohme LLC | $11.35 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Enright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.